Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Neotigason

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

18 API Suppliers, 10 USDMF, 6 CEP/COS, 3 EU WC, 7 NDC API, 5 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

118 FDF Dossiers, 23 FDA Orange Book, 72 Europe, 6 Canada, 4 Australia, 4 South Africa, 9 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 17.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 22.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 SPI Pharma, 7 DKSH, 3 Boai NKY Pharmaceuticals Ltd, 2 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 2 Kirsch Pharma, 4 ACG Worldwide, 1 Actylis, 1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 18 BASF, 2 DFE Pharma, 1 Esteem Industries, 1 Finar, 6 Gangwal Chemicals, 1 Ideal Cures, 1 Kerry, 1 Keval Exports, 3 Lonza Capsugel, 3 Microlex e.U, 2 Nanjing Bold Chemical, 1 Nitika Pharmaceutical Specialities, 1 Novo Excipients, 2 Pharmatrans-Sanaq, 2 Pluviaendo, 1 Prachin Chemical, 1 Qualicaps, 14 Roquette, 1 Seppic, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 8 Sigachi Industries, 1 Silverline Chemicals, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

31 Fillers, Diluents & Binders, 21 Thickeners and Stabilizers, 16 Granulation, 15 Solubilizers, 15 Direct Compression, 11 Coating Systems & Additives, 8 Co-Processed Excipients, 8 Film Formers & Plasticizers, 8 Empty Capsules, 7 Topical, 7 Controlled & Modified Release, 7 Taste Masking, 6 Parenteral, 5 Disintegrants & Superdisintegrants, 4 Lubricants & Glidants, 4 Chewable & Orodispersible Aids, 3 Coloring Agents, 3 Emulsifying Agents, 2 Surfactant & Foaming Agents, 1 Rheology Modifiers

DIGITAL CONTENT

3 News #PharmaBuzz

3 News #PharmaBuzz

GLOBAL SALES INFORMATION

5 US Medicaid Prescriptions, 15 Regulatory FDF Prices

MARKET PLACE

9 APIs, 3 FDF Dossiers

REF. STANDARDS & IMPURITIES

2 EDQM, 3 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
29/11/2025	BASF	Germany	BASF SE Ludwigshafen DE	R1-CEP 2007-201 - Rev 00	Acitretin	2013-11-15	Withdrawn by Holder	Chemical	2018-07-05	1385
29/11/2025	Chongqing Huapont Pharmaceutical	China	CHONGQING HUAPONT SHENGCHEM PHARMACEUTICAL CO., LTD. Chongqing CN	CEP 2021-012 - Rev 01	Acitretin, Process 2	2025-08-20	Valid	Chemical		1385

Neotigason

Neotigason

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

18 API Suppliers

10 USDMF

6 CEP/COS

3 EU WC

7 NDC API

5 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

3 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

118 FDF Dossiers

23 FDA Orange Book

72 Europe

6 Canada

4 Australia

4 South Africa

9 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 17.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 22.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 SPI Pharma

7 DKSH

3 Boai NKY Pharmaceuticals Ltd

2 Gangwal Healthcare

3 Nanjing Well Pharmaceutical

2 Kirsch Pharma

4 ACG Worldwide

1 Actylis

1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Ashland

18 BASF

2 DFE Pharma

1 Esteem Industries

1 Finar

6 Gangwal Chemicals

1 Ideal Cures

1 Kerry

1 Keval Exports

3 Lonza Capsugel

3 Microlex e.U

2 Nanjing Bold Chemical

1 Nitika Pharmaceutical Specialities

1 Novo Excipients

2 Pharmatrans-Sanaq

2 Pluviaendo

1 Prachin Chemical

1 Qualicaps

14 Roquette

1 Seppic

1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

8 Sigachi Industries

1 Silverline Chemicals

1 Ulanqab Kema New Material

1 Valens Pharmachem

1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

31 Fillers, Diluents & Binders

21 Thickeners and Stabilizers

16 Granulation

15 Solubilizers

15 Direct Compression

11 Coating Systems & Additives

8 Co-Processed Excipients

8 Film Formers & Plasticizers

8 Empty Capsules

7 Topical

7 Controlled & Modified Release

7 Taste Masking

CAPSULE;ORAL - 10MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - 17.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - 22.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - 25MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons